🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07805512
Starting soon Not applicable

A Study to Evaluate the Effectiveness and Safety of Restylane Shaype in the Improvement of Jawline Definition

NCT07805512 · tracked via the Priya Life Science China tracker
Sponsor
Galderma R&D
Phase
Not applicable
Started
2026-09
Last updated
2026-09-15

Condition(s) studied

Jawline Definition

Investigational drug(s) / intervention(s)

Restylane Shaype

Restylane Shaype: Restylane Shaype is an injectable, sterile, transparent, biodegradable gel of non-animal crosslinked sodium hyaluronate. Restylane Shaype has the addition of lidocaine hydrochloride. They are supplied in a glass syringe.

Study summary

This is a randomized, evaluator-blinded, parallel group, no-treatment controlled, multicenter study to evaluate effectiveness and the safety of Restylane Shaype for improvement of jawline definition in China. Subjects of Chinese origin, age 18 years, who are eligible for treatment to improve jawline definition. Study sites is approximately 6.

A total of approximately 162 subjects will be randomized (2:1) to either treatment with Restylane Shaype Treatment Group (approximately 108subjects) or no-treatment Control Group (approximately 54 subjects).

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Males and non-pregnant, non-breastfeeding females of Chinese origin and aged 18 years or older. 2. Intent to receive bilateral jawline definition treatment. Exclusion Criteria: 1. Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) gel or to gram positive bacterial proteins. 2. Known/previous allergy or hypersensitivity to local anesthetics, e.g. lidocaine or other amide-type anesthetics. 3. Previous or present multiple allergies or severe allergies, such as manifested by anaphylaxis or angioedema, or family history of these conditions. 4. Prior surgery in the treatment area that in the Treatment investigator's opinion could interfere with the study safety and/or effectiveness assessments. 5. Any previous aesthetic procedures or implants. 6. Presence of any disease or lesions near or in the area to be treated.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Galderma Investigational Site #6340 Beijing Beijing Municipality

More Galderma R&D trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07805512 on ClinicalTrials.gov ↗ ← All trials in China